Cochrane Abstracts
Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Poly(ADP‐ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer." Cochrane Abstracts, John Wiley & Sons, Inc, 2025. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/438488/all/Poly_ADP‐ribose__polymerase__PARP__inhibitors_for_the_treatment_of_ovarian_cancer.
Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Abstracts. John Wiley & Sons, Inc; 2025. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438488/all/Poly_ADP‐ribose__polymerase__PARP__inhibitors_for_the_treatment_of_ovarian_cancer. Accessed March 24, 2025.
Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. (2025). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/438488/all/Poly_ADP‐ribose__polymerase__PARP__inhibitors_for_the_treatment_of_ovarian_cancer
Poly(ADP‐ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2025. [cited 2025 March 24]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/438488/all/Poly_ADP‐ribose__polymerase__PARP__inhibitors_for_the_treatment_of_ovarian_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
ID - 438488
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/438488/all/Poly_ADP‐ribose__polymerase__PARP__inhibitors_for_the_treatment_of_ovarian_cancer
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
